Skip to main content
European Commission logo
Live, work, travel in the EU
COVID-19 In Vitro Diagnostic Devices and Test Methods Database

Scientific literature on COVID-19 Test Methods and Devices - detail

Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2

DOI
10.1016/j.jinf.2020.06.023 
Detection Principle
ImmunoAssay-Antibody
Target
IgG. IgM vs N or S
Testing Method Category
 
Testing Method
Kits (LFIA)
Testing Method - Additional Info
point-of-care (POC) lateral flow immunoassays (LFIA) (ALLTEST 2019-nCoV IgG/IgM Rapid Test, Dynamiker 2019-nCoV IgG/IgM Rapid Test, ASK COVID-19 IgG/IgM Rapid Test, and Wondfo SARS-CoV-2 Antibody Test)
Reported Performance
Sensitivity: 100% (overall, >21 dpo), 50% (ALLTEST 1-14 dpo), 97.5% (ALLTEST 15-21 dpo), 41.3% (Dynamiker 1-14 dpo), 87% (Dynamiker 15-21 dpo), 47.8% (ASK 1-14 dpo), 87% (ASK 15-21 dpo), 52.2% (Wondfo 1-14 dpo), 91.3% (Wondfo 15-21 dpo); Specificity: 100% (overall, >21 dpo); 100% (overall, 1-14dpo), 100% (overall, 15-21 dpo)
Sample Size
16 PCR positive 58 PCR negative patients
Peer-reviewed
yes

The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements